Note 4 - Other Financial Information

9 Months Ended

Sep. 30, 2025

Note 4 – Other Financial Information

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following as of September 30, 2025 and December 31, 2024 (in thousands):

	*September 30,*		*December 31,*
	*2025*		*2024*
Accounts payable	$	10,279	$	10,931
Accrued sales reserves		7,700		5,151
Accrued clinical expenses		1,892		2,027
Accrued research and development expenses		737		2,173
Accrued selling, general and administrative expenses		4,414		6,000
Accrued other expenses		1,151		1,149
Total accounts payable and accrued expenses	$	26,173	$	27,431

Interest and Other Income, Net

Interest and other income, net consisted of the following for the three and nine months ended September 30, 2025 and 2024 (in thousands):

	*Three Months Ended September 30,*						*Nine Months Ended September 30,*
	*2025*			*2024*			*2025*			*2024*
Interest income	$	1,176		$	2,757		$	5,057		$	6,089
Other loss, net		(197	)		(158	)		(665	)		(167	)
Total interest and other income, net	$	979		$	2,599		$	4,392		$	5,922

UroGen Pharma Ltd. 10-Q